MPR Weekly Dose 83 - Rx-to-OTC for allergy spray; Novel contraceptive; Pediatric VTE Tx; Veklury real world efficacy data; Wearable thermometer

This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Meanwhile, real-world data on the efficacy of the COVID-`9 treatment remdesivir has been published.

Episode metadata supplied by the publisher feed · Published Jun 24, 2021

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose 83 - Rx-to-OTC for allergy spray; Novel contraceptive; Pediatric VTE Tx; Veklury real world efficacy data; Wearable thermometer

0:00 10:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 10 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on June 24, 2021.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!